These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 22331039)

  • 1. Durable clinical activity of single-agent bevacizumab in a nonagenarian patient with metastatic alveolar soft part sarcoma.
    Mir O; Boudou-Rouquette P; Larousserie F; Blanchet B; Babinet A; Anract P; Goldwasser F
    Anticancer Drugs; 2012 Aug; 23(7):745-8. PubMed ID: 22331039
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vascular-endothelial-growth-factor (VEGF) expression and possible response to angiogenesis inhibitor bevacizumab in metastatic alveolar soft part sarcoma.
    Azizi AA; Haberler C; Czech T; Gupper A; Prayer D; Breitschopf H; Acker T; Slavc I
    Lancet Oncol; 2006 Jun; 7(6):521-3. PubMed ID: 16750504
    [No Abstract]   [Full Text] [Related]  

  • 3. Necrosis of a skin autograft after short-term treatment with sunitinib in a 14-year-old girl with metastatic alveolar soft part sarcoma of the thigh.
    Hanzer M; Nebl A; Spendel S; Pilhatsch A; Urban C; Benesch M
    Klin Padiatr; 2010 May; 222(3):184-6. PubMed ID: 20514624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of multidrug resistant advanced alveolar soft part sarcoma with sunitinib.
    Ghose A; Tariq Z; Veltri S
    Am J Ther; 2012 Jan; 19(1):e56-8. PubMed ID: 20634674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiangiogenic treatment as a pre-operative management of alveolar soft-part sarcoma.
    Conde N; Cruz O; Albert A; Mora J
    Pediatr Blood Cancer; 2011 Dec; 57(6):1071-3. PubMed ID: 21744483
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alveolar soft part sarcoma in childhood: is Sunitinib-Sutent® treatment an effective approach?
    Hilbert M; Mary P; Larroquet M; Serinet MO; Helfre S; Brisse H; Coulomb A; Orbach D
    Pediatr Blood Cancer; 2012 Mar; 58(3):475-6. PubMed ID: 22234817
    [No Abstract]   [Full Text] [Related]  

  • 7. Advanced alveolar soft part sarcoma responds to apatinib.
    Zhou Y; Tang F; Wang Y; Min L; Luo Y; Zhang W; Shi R; Duan H; Tu C
    Oncotarget; 2017 Jul; 8(30):50314-50322. PubMed ID: 28679123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term results of therapy with sunitinib in metastatic alveolar soft part sarcoma.
    Jagodzińska-Mucha P; Świtaj T; Kozak K; Koseła-Paterczyk H; Klimczak A; Ługowska I; Rogala P; Wągrodzki M; Falkowski S; Rutkowski P
    Tumori; 2017 May; 103(3):231-235. PubMed ID: 28291905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effective treatment of advanced alveolar soft part sarcoma with sunitinib: A case report.
    Ye C; Wang J; Li W; Yuan M; Chai Y
    Medicine (Baltimore); 2018 Dec; 97(51):e13584. PubMed ID: 30572461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnosis, Prognosis, and Treatment of Alveolar Soft-Part Sarcoma: A Review.
    Paoluzzi L; Maki RG
    JAMA Oncol; 2019 Feb; 5(2):254-260. PubMed ID: 30347044
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brain Metastases and Place of Antiangiogenic Therapies in Alveolar Soft Part Sarcoma: A Retrospective Analysis of the French Sarcoma Group.
    Malouf GG; Beinse G; Adam J; Mir O; Chamseddine AN; Terrier P; Honore C; Spano JP; Italiano A; Kurtz JE; Coindre JM; Blay JY; Le Cesne A
    Oncologist; 2019 Jul; 24(7):980-988. PubMed ID: 30626710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Treatment and prognosis of stage IV alveolar soft part sarcoma].
    Zhao J; Yang Y
    Zhonghua Zhong Liu Za Zhi; 2012 Dec; 34(12):932-6. PubMed ID: 23336381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. iCREATE: imaging features of primary and metastatic alveolar soft part sarcoma from the EORTC CREATE study.
    Mcaddy NC; Saffar H; Litière S; Jespers P; Schöffski P; Messiou C
    Cancer Imaging; 2020 Oct; 20(1):79. PubMed ID: 33121537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A rare tumour with a distinctive histological appearance].
    Pavageau AH; Croué A; Reguerre Y; Rialland X; Rousselet MC
    Ann Pathol; 2010 Apr; 30(2):152-4. PubMed ID: 20451077
    [No Abstract]   [Full Text] [Related]  

  • 15. [Clinical features and prognosis of alveolar soft part sarcoma].
    Xu LB; Yu SJ; Shao YF; Zhang HT; Zhao ZG
    Zhonghua Zhong Liu Za Zhi; 2007 Oct; 29(10):778-80. PubMed ID: 18396693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Antiangionic drugs in soft tissue sarcoma].
    Salas S; Huynh T; Deville JL; Duffaud F
    Bull Cancer; 2010 Jun; 97(6):701-5. PubMed ID: 20483703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cediranib phase-II study in children with metastatic alveolar soft-part sarcoma (ASPS).
    Cohen JW; Widemann BC; Derdak J; Dombi E; Goodwin A; Dompierre J; Onukwubiri U; Steinberg SM; O'Sullivan Coyne G; Kummar S; Chen AP; Glod J
    Pediatr Blood Cancer; 2019 Dec; 66(12):e27987. PubMed ID: 31502400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined immunotherapy and targeted treatment for primary alveolar soft part sarcoma of the lung: case report and literature review.
    Su H; Yu C; Ma X; Song Q
    Invest New Drugs; 2021 Oct; 39(5):1411-1418. PubMed ID: 33765213
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies.
    Shih T; Lindley C
    Clin Ther; 2006 Nov; 28(11):1779-802. PubMed ID: 17212999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metastatic alveolar soft part sarcoma presenting as a dural-based cerebral mass.
    Perry JR; Bilbao JM
    Neurosurgery; 1994 Jan; 34(1):168-70. PubMed ID: 8121554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.